For the year ending 2025-12-31, TCRX made $10,325K in revenue. -$129,817K in net income. Net profit margin of -1257.31%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Collaboration and license revenue | 10,325 | |||
| Research and development | 114,150 | |||
| General and administrative | 31,988 | |||
| Total operating expenses | 146,138 | |||
| Loss from operations | -135,813 | |||
| Interest and other income, net | 8,816 | |||
| Interest expense | 2,769 | |||
| Total other income | 6,047 | |||
| Net loss | -129,766 | |||
| Unrealized gain (loss) on available-for-sale securities | -51 | |||
| Comprehensive loss | -129,817 | |||
| Basic EPS | -1 | |||
| Diluted EPS | -1 | |||
| Basic Average Shares | 129,777,415 | |||
| Diluted Average Shares | 129,777,415 | |||
TScan Therapeutics, Inc. (TCRX)
TScan Therapeutics, Inc. (TCRX)